logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回
陆

陆舜 (Shun Lü)

shanghai jiao tong university school of medicine

78H指数
903论文数
3.7W被引数
收录论文 234
发表时间
logo
Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial口服KRAS G12D抑制剂GFH375用于既往治疗过的KRASG12D突变晚期实体瘤：一项1期临床试验
errNature Medicine
IF50
err2026-09-15
err0
PREAI
errXinghao Ai; Zhengbo Song; Lin Wu; Aiping Zhou; Di Cheng; Hong Zong; Heshui Wu; Zuoxing Niu; Yuping Sun; Lingjun Zhu; Zhiwei Li; Yanhong Deng; Ying Yuan; Xiujuan Qu; Haitao Zhao; Yingying Du; Ziming Li; Yu Wang; Haige Shen; Huaqiang Zhu; Chanli Zheng; Shuang Wang; Zhao Cui; Lingyu Tai; Shun Lu
err分享
err收藏
A Simple Scoring Model for Mid-term Remission of Type 2 Diabetes Mellitus After Sleeve Gastrectomy in Chinese Patients中国患者袖状胃切除术后的2型糖尿病中期缓解的简易评分模型
errObesity Surgery
IF3.1
err2026-09-12
err0
PREAI
errShun Lu; Mengcheng He; Qiyuan Yao; Rong Hua; Bo Xu; Qiwei Shen; Xiaojian Fu; Chongwen Zhan; Jie Gu; Yikai Shao
err分享
err收藏
Real-world treatment pattern and clinical outcomes in Chinese NSCLC patients with KRAS G12C mutation
errBMC Cancer
IF3.4
err2026-07-30
err0
errOAAI
errLan Shen; Yibo Gao; Zhengbo Song; Qiming Wang; Qiaoxia Zhou; Yan Lei; Shun Lu; Ziming Li
err分享
err收藏
AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50%AdvantTIG-302：奥昔匹鲁单抗（抗TIGIT）联合替雷利珠单抗（抗PD-1）对比帕博利珠单抗治疗PD-L1≥50%的未经治疗、局部晚期、不可切除或转移性非小细胞肺癌的III期研究
errJournal of Thoracic Oncology
IF20.8
err2026-07-14
err0
PREAI
errMark A. Socinski; Martin Reck; Luis Paz-Ares; Makoto Nishio; Alexander I. Spira; Xinmin Yu; Tamar Melkadze; Aiping Zeng; Alejandro Martinez-Bueno; Xingya Li; Surein Arulananda; Yunxia Zuo; Sandra Chica-Duque; Wanjun Dai; Jincheng Zhou; Wei Tan; Shun Lu
err分享
err收藏
Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC: The ACTIVE Trial简报：奥莫替尼作为奥希替尼不耐受NSCLC患者的转换疗法：ACTIVE试验
errJournal of Thoracic Oncology
IF20.8
err2026-06-24
err0
errOAAI
errZiming Li; Biao Yao; Chun Huang; Conghua Xie; Renhua Guo; Jueping Feng; Wenxiu Yao; Hongyan Huang; Yongsheng Li; Yueyin Pan; Shun Lu
err分享
err收藏
Author Correction: A clinic-responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice作者更正: 来自临床应答者的定义微生物联盟可增强小鼠的anti-PD-1免疫疗法功效
errNature Microbiology
IF19.4
err2026-06-16
err0
PREAI
errHaiyan Zhou; Ruiming Sun; Xiaoqun Nie; Liliang Xia; Hui Dong; Yujie Liu; Shurui Hou; Wenyue Dong; Xiaokuan Zhu; Yaxian Yao; Guo-Ping Zhao; Shun Lu; Ying Wang; Chen Yang
err分享
err收藏
Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study奥希替尼在不可切除III期EGFR突变非小细胞肺癌中序贯根治性放化疗后的安全性结局：III期LAURA研究
errLung Cancer
IF4.4
err2026-06-06
err0
PREAI
errTerufumi Kato; Xiaorong Dong; Toshiaki Takahashi; Nopadol Soparattanapaisarn; Sarayut Lucien Geater; Chih-Liang Wang; Edurne Arriola; Fedor Moiseenko; Lucy Thompson; Ellie Grainger; Elena Armenteros-Monterroso; Azura Evans; Ana Bolanos; Suresh S. Ramalingam; Shun Lu
err分享
err收藏
MYBL2 impedes cisplatin sensitivity through suppressing GSDME-mediated pyroptosis in lung adenocarcinoma.MYBL2通过抑制GSDME介导的焦亡而降低肺腺癌对顺铂的敏感性。
errCell Death Discovery
IF7
err2026-06-02
err0
errOAAI
errTingting Lu; Jie Zhang; Wendi Xuzhang; Xiru Quan; Guangling Jie; Ziming Li; Shun Lu
err分享
err收藏
TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with EGFR -mutated locally advanced or metastatic non-small cell lung cancerTROPION-Lung14研究方案：一项关于奥希替尼联合达托帕姆德鲁克坦与奥希替尼单药作为携带EGFR突变局部晚期或转移性非小细胞肺癌患者一线治疗的III期研究
errTherapeutic Advances in Medical Oncology
IF4.2
err2026-05-20
err0
PREAI
errShun Lu; Mariano Provencio Pulla; Eldsamira Mascarenhas; Junko Tanizaki; Hye Ryun Kim; Yinglei Liu; Shengmei Feng; Biao Zhang; Laurence Toms; James Chih-Hsin Yang; Sarah B. Goldberg
err分享
err收藏
International Consensus on Severe Lung Cancer-The Second Edition国际重症肺癌共识（第二版）
errTranslational Lung Cancer Research
IF3.5
err2026-04-30
err0
PREAI
errLin, Xinqing; Chu, Qian; Dong, Yuchao; Li, Min; Lv, Tangfeng; Lin, Gen; Sang, Ling; Tian, Panwen; Xia, Yang; Xie, Zhanhong; Chen, Haiming; Hong, Cheng; Jiang, Juan; Jin, Haoru; Kuai, Zhongkai; Liu, Ming; Luo, Weizhan; Luo, Yongbei; Miao, Qian; Mo, Wei; Pu, Dan; Qiu, Yuan; Qian, Zhe; Sun, Jiancong; Shi, Hui; Sun, Qinying; Sun, Yutao; Yu, Zihui; Xie, Xiaohong; Xu, Wanting; Yi, Minxiao; Yuan, Dongmei; Zhang, Longfeng; Zhao, Fei; Zhong, Changhao; Zhan, Ping; Zheng, Xiaobin; Bai, Cunxue; Chen, Enguo; Chen, Rui; Chen, Xin; Cheng, Yuan; Chen, Quanfang; Cai, Linbo; Cai, Xiuyu; Chen, Liangan; Chen, Yan; Dong, Wen; Deng, Haiyi; Fang, Wenfeng; Gan, Xin; Hao, Yue; Hu, Weidong; He, Yong; Hu, Yi; Hu, Jie; Han, Baohui; Hu, Chengping; Hu, Minjuan; Jiang, Yongliang; Jin, Yang; Liu, Dan; Liu, Weiting; Li, Wen; Li, Jing; Liu, Laiyu; Liu, Jun; Li, Weifeng; Liang, Wenhua; Lin, Jie; Liu, Hongbing; Li, Ziming; Li, Weimin; Lu, NiHong; Lu, Shun; Mu, Chuanyong; Ma, Hongxia; Miao, Liyun; Mu, Xinlin; Pu, Xingxiang; Peng, Jing; Peng, Hongbing; Qin, Jianwen; Qin, Yinyin; Ren, Shengxiang; Sun, Longhua; Su, Chunxia; Song, Yong; Tan, Xiaowu; Tang, Kejing; Tang, Xiaomei; Tong, Jianlin; Wang, Wenxian; Wu, Di; Wu, Lin; Wang, Mengzhao; Wang, Huijuan; Wang, Yuehong; Wang, Hongmei; Wang, Qi; Wang, Zhijie; Wang, Jie; Wang, Kai; Wang, Fei; Xu, Chunwei; Xie, Min; Xu, Aiguo; Xiao, Kui; Xu, Xin; Xu, Fei; Ye, Xianwei; Yang, Meng; Yang, Boyan; Ye, Xiaoqun; Ye, Feng; Yu, Zongyang; Yue, Dongsheng; Zhang, Qichuan; Zou, Juntao; Zhang, Jian; Zhuang, Li; Zhou, Jianying; Zhou, Jianya; Zhang, Bicheng; Zhang, Jian; Zhang, Jianqing; Zhang, Xiaoju; Zhao, Wei; Zhu, Bo; Zhu, Zhengfei; Zhong, Wenzhao; Zhou, Caicun; Zhou, Yanbin; He, Jianxing; Zhong, Nanshan; Saito, Yuichi; Watanabe, Satoshi; Petrella, Francesco; Nakada, Takeo; Goto, Taichiro; Fiorelli, Alfonso; Solli, Piergiorgio; Berardi, Rossana; Ichiki, Yoshinobu; Braun, Marcin; Nagasaka, Misako; Chouaid, Christos; Thawani, Rajat; Santa-Catalina, Pedro Gonzalez; Styrvoky, Kim; Abbar, Baptiste; Provencio, Mariano; Li, Shiyue; Chen, Rongchang; Zhou, Chengzhi
err分享
err收藏
SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in ChinaSKYSCRAPER-02C：一项在中国进行的一项针对未经治疗的广泛期小细胞肺癌患者的、评估阿替利珠单抗联合卡铂和依托泊苷，无论是否联用替拉格鲁单抗的、随机、双盲、安慰剂对照的III期研究
errJournal of Thoracic Oncology
IF20.8
err2026-04-06
err0
errOAAI
errShun Lu; Jian Fang; Yan Yu; Yun Fan; Xiaorong Dong; Ziping Wang; Qiming Wang; Jialei Wang; Jiuwei Cui; Hongming Pan; Qiong Wu; Chanjuan Lin; Li Zhang; Raymond Meng; Chang Liu; Xiayu Huang; Namrata S. Patil
err分享
err收藏
Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort奥希替尼在不可切除的III期EGFR突变非小细胞肺癌患者中接受根治性放化疗后的应用：LAURA中国队列
errLung Cancer
IF4.4
err2026-02-23
err0
errOAAI
errXiaorong Dong; Hong Jian; Meijuan Huang; Shuanghu Yuan; Zhengfei Zhu; Lin Wu; Ming Chen; Nan Bi; Yi Pan; Yingyi Wang; Dongqing Lv; Elena Armenteros Monterroso; Xiangning Huang; Rui Mao; Wei Fu; Yi Zhao; Shun Lu
err分享
err收藏
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis
errLung Cancer
IF4.4
err2026-02-04
err0
PREAI
errHidetoshi Hayashi; Byoung Chul Cho; Yu Jung Kim; Se-Hoon Lee; Pongwut Danchaivijitr; Adlinda Alip; Hailin Xiong; Soon-Hin How; Gee-Chen Chang; James Chih-Hsin Yang; Yuta Yamanaka; Mehmet Ali Nahit Şendur; Kumar Prabhash; Koichi Azuma; Alianu Akawung; Elizabeth Fennema; Xiaodan Tang; Sujay Shah; Seema Sethi; Shun Lu
err分享
err收藏
Plain language summary of the ALINA study results: alectinib compared with chemotherapy after surgery in people with ALK-positive non-small cell lung cancerALINA研究结果的大众语言摘要：alectinib与化疗相比，在ALK阳性非小细胞肺癌患者术后的应用
errFuture Science OA
IF2.1
err2025-12-31
err0
PREAI
errWu, Yi-Long; Dziadziuszko, Rafal; Ahn, Jin Seok; Barlesi, Fabrice; Nishio, Makoto; Lee, Dae Ho; Lee, Jong-Seok; Zhong, Wenzhao; Horinouchi, Hidehito; Mao, Weimin; Hochmair, Maximilian; De Marinis, Filippo; Migliorino, Maria Rita; Bondarenko, Igor; Lu, Shun; Wang, Qun; Lohmann, Tania Ochi; Xu, Tingting; Cardona, Andres; Hiles, Laura; Noe, Johannes; Solomon, Benjamin J.
err分享
err收藏
A Response to the Letter to the Editor: “Comparable or Indeterminate? A Critical Appraisal of Efficacy Claims in the MARIPOSA Exploratory Analysis”对编辑信件的回应：“可比性或不确定性？对MARIPOSA探索性分析中疗效主张的批判性评估”
errJournal of Thoracic Oncology
IF20.8
err2025-12-03
err0
PREAI
errSe-Hoon Lee; Shun Lu; John Xie; Sujay Shah; Seema Sethi; Byoung Chul Cho
err分享
err收藏
Waste-to-Health Revolution: Upcycling Silk Sericin Byproducts into Circular Biomaterials for Biomedical Engineering
errBIOMACROMOLECULES
IF5.4
err2025-12-01
err0
PREAI
errXia, Shicheng; Yang, Jing; Wang, Zhaoyang; Lu, Shun; Wen, Shanshan; Guo, Kaiyu; Yang, Lei
err分享
err收藏
Entrectinib in Asian patients with ROS1 fusion-positive non-small cell lung cancer: updated efficacy and safety analysisEntrectinib在ROS1融合阳性非小细胞肺癌亚洲患者中的疗效和安全性：更新分析
errLung Cancer
IF4.4
err2025-11-21
err0
PREAI
errShun Lu; Yun Fan; Xiaorong Dong; Yan Yu; Juan Li; Jun Zhao; Chia-Chi Lin; Pengcheng Zhang; Yanjun Shi; Rui Luo; Xichun Hu
err分享
err收藏
Plasma proteomics profiling identifies predictive biomarkers for immunotherapy response in small-cell lung cancer血浆蛋白质组学分析鉴定出小细胞肺癌免疫治疗反应的预测性生物标志物
errLung Cancer
IF4.4
err2025-11-01
err0
errOAAI
errGuang-Ling Jie; Jia-Xin Zhong; Jing-Ze Wang; Zheng-Qi Cao; Xiao-Min Niu; Li-Liang Xia; Shun Lu
err分享
err收藏
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancerGLORY研究长期随访结果：gumarontinib在MET外显子14跳跃突变的东亚非小细胞肺癌患者中的II期研究
errTRANSLATIONAL LUNG CANCER RESEARCH
IF3.5
err2025-09-30
err0
PREAI
errLu, Shun; Yu, Yongfeng; Zhou, Jianya; Li, Xingya; Goto, Koichi; Min, Xuhong; Nishino, Kazumi; Cui, Jiuwei; Wu, Ling; Sakakibara, Jun; Shu, Yongqian; Dong, Xiaorong; Li, Lu; Yoneshima, Yasuto; Zhou, Chengzhi; Li, Xiaoling; Zhang, Yiping; Huang, Dingzhi; Zang, Aimin; Zhang, Wei; Wang, Xiuwen; Zhang, Li; Bai, Chong; Fang, Jian; Cao, Lejie; Zhao, Yanqiu; Yu, Yan; Shi, Meiqi; Zhong, Diansheng; Li, Fugen; Duanmu, Wenhao; Wang, Yibin
err分享
err收藏
Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study瑞格非尼单抗与安慰剂联合铂类化疗在一线非鳞状或鳞状转移性非小细胞肺癌患者中的比较（POD1UM-304）：一项三期、多区域、安慰剂对照、双盲、随机研究
errThe Lancet Respiratory Medicine
IF0
err2025-09-19
err0
PREAI
errShun Lu; Oleksandr Vynnychenko; Yaroslav Kulyaba; Vladimer Kuchava; Aishah Ibrahim; Fedor Moiseenko; Cagatay Arslan; Duong Thanh Nguyen; Marina Petrovic; Irfan Cicin; Khatuna Bibichadze; Timucin Cil; Jianhua Shi; Omer Fatih Olmez; Miranda Gogishvili; Mehmet Artac; Hoang Gia Nguyen; Mark Cornfeld; Chuan Tian; Mihaela C Munteanu; Claudia V M Sette; Igor Bondarenko
err分享
err收藏

研究方向

肺癌的靶向治疗与免疫治疗
合作学者
合作期刊
J
James Chih‐Hsin Yang
H 指数: 141 · 论文数: 1.2K
Y
Yi‐Long Wu
H 指数: 135 · 论文数: 2.2K
R
Roy S. Herbst
H 指数: 134 · 论文数: 1.3K
T
Tony Mok
H 指数: 131 · 论文数: 1.1K
E
Enriqueta Felip
H 指数: 129 · 论文数: 1.5K
查看更多